China National Pharmaceutical Group, also known as Sinopharm, is mulling a renewed offer for China Traditional Chinese Medicine Holdings that could value the drugmaker at roughly $4B, Bloomberg reports, citing people with knowledge of the matter said. Sinopharm, which holds a controlling stake in China TCM, is discussing a new bid with advisers to potentially take the company private at HK$6 per share. Reference Link
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on SHTDF: